Streetbeat News

Revenues

DNMR

Danimer Scientific projects its FY23 revenue to be $46.7 million, which is below the estimated $51.509 million.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 12:40 pm

MOGO

Mogo anticipates accelerating growth in its subscription and services revenue during FY24, projecting an overall growth rate in the mid-teens.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 12:38 pm

MOGO

Mogo Inc. (NASDAQ:MOGO) reported Q4 sales of $17.2M, surpassing the analyst consensus estimate of $16.386M by 4.97% and marking a 34.74% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 12:37 pm

CMG

Chipotle Mexican Grill Inc (NYSE:CMG) announced its first ever stock split, a 50-for-one split, after market close on Tuesday, aiming to make its stock more accessible. The stock split is pending shareholder approval at the annual meeting on June 6. Following the announcement, CMG shares rose, hitting new all-time highs. The company's revenue growth in FY23 was 14.32%, influenced by various factors including the macroeconomic environment. Economic conditions such as interest rates, inflation, and labor market strength could impact CMG's performance in the coming year.

Portfolio Pulse from Adam Eckert

March 20, 2024 | 12:24 pm

CHIQ

CQQQ

PDD

PDD Holdings Inc (NASDAQ:PDD) reported a significant year-on-year revenue growth of 123% in Q4 fiscal 2023, reaching $12.52 billion and surpassing consensus estimates of $11.01 billion. Adjusted earnings per ADS rose to $2.40, beating the consensus of $1.60. The company saw a 57% increase in online marketing services revenue and a 357% jump in transaction services revenue. PDD's adjusted operating profit grew by 112% to $3.46 billion. The company ended the quarter with $30.6 billion in cash and equivalents. PDD shares surged 15.7% in premarket trading. Investors can also gain exposure to PDD through the Global X MSCI China Consumer Discretionary ETF (NYSE:CHIQ) and the Invesco China Technology ETF (NYSE:CQQQ).

Portfolio Pulse from Anusuya Lahiri

March 20, 2024 | 12:09 pm

LUMO

Lumos Pharma has received a patent from the USPTO for a novel formulation of LUM-201, extending its exclusivity until 2042. This development could significantly impact Lumos Pharma's market position by potentially increasing its revenue streams and strengthening its competitive edge in the pharmaceutical industry through extended market exclusivity of LUM-201.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 12:06 pm

ACLS

Axcelis Technologies announced the shipment of multiple 150mm 'Purion M SiC Power Series' implanters to leading power device manufacturers in China. This move signifies Axcelis's expansion in the semiconductor industry, particularly in the silicon carbide (SiC) sector, which is crucial for power devices.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 12:05 pm

LRHC

La Rosa has acquired a real estate brokerage franchisee in California, marking its ninth acquisition since its IPO. The acquisition is part of La Rosa's strategy to launch a multi-level revenue share plan in the state, aimed at providing realtors with a new income stream. This move is in line with La Rosa's goal to achieve $100 million in annualized revenue by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 12:02 pm

HES

Hess Corporation (NYSE:HES) has been analyzed by 5 analysts in the last three months, showing a shift towards a more neutral stance with 4 indifferent ratings recently. The average 12-month price target for HES has been raised to $177.0, marking a 4.0% increase from the previous target of $170.20. Analysts from firms like Mizuho and Piper Sandler have adjusted their price targets, reflecting evolving market conditions and Hess's performance. Despite positive revenue growth, Hess faces challenges in net margin, ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 12:01 pm

FUSN

Fusion Pharmaceuticals (NASDAQ:FUSN) has received mixed analyst ratings over the past three months, with a notable shift towards a more neutral stance in the last 30 days. Analysts have updated their price targets, reflecting an average target of $17.82, which is a 34.8% increase from the previous average of $13.22. This adjustment suggests a positive outlook on Fusion Pharmaceuticals' future market performance. The company, a clinical-stage biopharmaceutical firm focused on developing therapies for cancer, has shown significant revenue growth and a strong net margin, despite a below-average return on assets.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 12:01 pm